{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:38:22Z","timestamp":1792543102992,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":98,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hochschuljubil\u00e4umsfonds der Stadt Wien","award":["Project H-334533\/2021"],"award-info":[{"award-number":["Project H-334533\/2021"]}]},{"name":"Medical Scientific Fund of the Mayor of the City of Vienna","award":["23096"],"award-info":[{"award-number":["23096"]}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["10.55776\/P35978"],"award-info":[{"award-number":["10.55776\/P35978"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 has evolved into several genetic variants, all bearing mutations that reduce antibody binding and affect vaccine and treatment effectiveness. Updated COVID-19 vaccines, including bivalent formulations (wild type [WT]\/BA.1 or WT\/BA.5) and more recent monovalent versions targeting emerging variants such as XBB.1.5, JN.1, KP.2 or LP.8.1, were developed to broaden protection. However, immune imprinting may limit the induction of neutralizing antibodies against strains that differ significantly, even after receiving several variant-specific boosters. A deeper understanding of how booster vaccination reshapes antibody specificity remains essential for rational vaccine design. We examined the antibody response to a bivalent WT\/BA.5 booster, focusing on antibody levels and neutralization. Serum samples collected before and after a fourth dose of monovalent WT or bivalent (WT\/BA.5) mRNA vaccines were compared with sera from individuals after primary WT infections and Omicron BA.1, BA.2, or BA.5 breakthrough infections. We found that both monovalent and bivalent boosters significantly increased IgG and neutralizing antibodies, but breakthrough infections induced broader cross-reactive responses. Depletion experiments revealed that booster-induced immunity was predominantly mediated by cross-reactive antibodies, with the highest levels after breakthrough infections and the lowest after a primary WT infection. These findings provide functional insights into the antibody specificities associated with imprinting effects following variant-adapted booster vaccination.<\/jats:p>","DOI":"10.1038\/s41598-026-62635-8","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:45:29Z","timestamp":1784123129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Variant-specific and cross-reactive antibody responses following COVID-19 booster vaccinations and SARS-CoV-2 breakthrough infections"],"prefix":"10.1038","volume":"16","author":[{"given":"Iris","family":"Medits-Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Springer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan W.","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith H.","family":"Aberle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Stiasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"62635_CR1","doi-asserted-by":"publisher","unstructured":"Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, 44\u201357. https:\/\/doi.org\/10.1016\/j.chom.2020.11.007 (2021).","DOI":"10.1016\/j.chom.2020.11.007"},{"key":"62635_CR2","doi-asserted-by":"publisher","first-page":"106092","DOI":"10.1016\/j.antiviral.2025.106092","volume":"235","author":"Q Wu","year":"2025","unstructured":"Wu, Q. et al. Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients. Antiviral Res. 235, 106092. https:\/\/doi.org\/10.1016\/j.antiviral.2025.106092 (2025).","journal-title":"Antiviral Res."},{"key":"62635_CR3","doi-asserted-by":"publisher","first-page":"101291","DOI":"10.1016\/j.xcrm.2023.101291","volume":"4","author":"JN Faraone","year":"2023","unstructured":"Faraone, J. N. & Liu, S. L. Immune imprinting as a barrier to effective COVID-19 vaccines. Cell. Rep. Med. 4, 101291. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101291 (2023).","journal-title":"Cell. Rep. Med."},{"key":"62635_CR4","doi-asserted-by":"publisher","unstructured":"Wang, Q. et al. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe 32, 315\u2013321. https:\/\/doi.org\/10.1016\/j.chom.2024.01.014 (2024).","DOI":"10.1016\/j.chom.2024.01.014"},{"key":"62635_CR5","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/S1473-3099(25)00058-1","volume":"25","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2. Lancet. Infect. Dis. 25, e133\u2013e134. https:\/\/doi.org\/10.1016\/S1473-3099(25)00058-1 (2025).","journal-title":"Lancet. Infect. Dis."},{"key":"62635_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s43856-025-00898-4","volume":"5","author":"XH Wrynla","year":"2025","unstructured":"Wrynla, X. H. et al. Immune imprinting and vaccine interval determine antibody responses to monovalent XBB.1.5 COVID-19 vaccination. Commun. Med. (Lond). 5, 182. https:\/\/doi.org\/10.1038\/s43856-025-00898-4 (2025).","journal-title":"Commun. Med. (Lond)"},{"key":"62635_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-025-01255-x","author":"R Uraki","year":"2025","unstructured":"Uraki, R., Korber, B., Diamond, M. S. & Kawaoka, Y. SARS-CoV-2 variants: biology, pathogenicity, immunity and control. Nat. Rev. Microbiol. https:\/\/doi.org\/10.1038\/s41579-025-01255-x (2025).","journal-title":"Nat. Rev. Microbiol."},{"key":"62635_CR8","doi-asserted-by":"publisher","unstructured":"Zhou, Z., Barrett, J. & He, X. Immune Imprinting and Implications for COVID-19. Vaccines (Basel). 11, 859. https:\/\/doi.org\/10.3390\/vaccines11040875 (2023).","DOI":"10.3390\/vaccines11040875"},{"key":"62635_CR9","doi-asserted-by":"publisher","unstructured":"Johnston, T. S. et al. Immunological imprinting shapes the specificity of human antibody responses against SARS-CoV-2 variants. Immunity 57, 912\u2013925. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.017 (2024).","DOI":"10.1016\/j.immuni.2024.02.017"},{"key":"62635_CR10","doi-asserted-by":"publisher","unstructured":"Roltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025\u20131040. https:\/\/doi.org\/10.1016\/j.cell.2022.01.018 (2022).","DOI":"10.1016\/j.cell.2022.01.018"},{"key":"62635_CR11","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.immuni.2024.02.016","volume":"57","author":"MA Tortorici","year":"2024","unstructured":"Tortorici, M. A. et al. Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans. Immunity 57, 904\u2013911. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.016 (2024). e904.","journal-title":"Immunity"},{"key":"62635_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent omicron-containing booster vaccine against Covid-19. N Engl. J. Med. 387, 1279\u20131291. https:\/\/doi.org\/10.1056\/NEJMoa2208343 (2022).","journal-title":"N Engl. J. Med."},{"key":"62635_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMp2215780","volume":"388","author":"PA Offit","year":"2023","unstructured":"Offit, P. A. Bivalent Covid-19 vaccines - a cautionary tale. N Engl. J. Med. 388, 481\u2013483. https:\/\/doi.org\/10.1056\/NEJMp2215780 (2023).","journal-title":"N Engl. J. Med."},{"key":"62635_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41591-022-02162-x","volume":"29","author":"C Kurhade","year":"2023","unstructured":"Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 29, 344\u2013347. https:\/\/doi.org\/10.1038\/s41591-022-02162-x (2023).","journal-title":"Nat. Med."},{"key":"62635_CR15","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1056\/NEJMc2214916","volume":"388","author":"J Zou","year":"2023","unstructured":"Zou, J. et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl. J. Med. 388, 854\u2013857. https:\/\/doi.org\/10.1056\/NEJMc2214916 (2023).","journal-title":"N Engl. J. Med."},{"key":"62635_CR16","doi-asserted-by":"publisher","first-page":"e0360724","DOI":"10.1128\/mbio.03607-24","volume":"16","author":"JM Carreno","year":"2025","unstructured":"Carreno, J. M. et al. XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies. mBio 16, e0360724. https:\/\/doi.org\/10.1128\/mbio.03607-24 (2025).","journal-title":"mBio"},{"key":"62635_CR17","doi-asserted-by":"publisher","first-page":"106681","DOI":"10.1016\/j.jinf.2026.106681","volume":"92","author":"D Geers","year":"2026","unstructured":"Geers, D. et al. Preferential boosting of SARS-CoV-2 Omicron lineage-specific immune responses by monovalent XBB.1.5 vaccination. J. Infect. 92, 106681. https:\/\/doi.org\/10.1016\/j.jinf.2026.106681 (2026).","journal-title":"J. Infect."},{"key":"62635_CR18","doi-asserted-by":"publisher","first-page":"e1010592","DOI":"10.1371\/journal.ppat.1010592","volume":"18","author":"AJ Greaney","year":"2022","unstructured":"Greaney, A. J. et al. The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. PLoS Pathog. 18, e1010592. https:\/\/doi.org\/10.1371\/journal.ppat.1010592 (2022).","journal-title":"PLoS Pathog"},{"key":"62635_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"CY Liang","year":"2024","unstructured":"Liang, C. Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960. https:\/\/doi.org\/10.1038\/s41586-024-07539-1 (2024).","journal-title":"Nature"},{"key":"62635_CR20","doi-asserted-by":"publisher","first-page":"127459","DOI":"10.1016\/j.vaccine.2025.127459","volume":"62","author":"MM Schmitt","year":"2025","unstructured":"Schmitt, M. M. et al. Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns. Vaccine 62, 127459. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127459 (2025).","journal-title":"Vaccine"},{"key":"62635_CR21","doi-asserted-by":"publisher","first-page":"101474","DOI":"10.1016\/j.xcrm.2024.101474","volume":"5","author":"A Abbad","year":"2024","unstructured":"Abbad, A. et al. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5. Cell. Rep. Med. 5, 101474. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101474 (2024).","journal-title":"Cell. Rep. Med."},{"key":"62635_CR22","doi-asserted-by":"publisher","first-page":"eadu4107","DOI":"10.1126\/sciimmunol.adu4107","volume":"10","author":"SK Malladi","year":"2025","unstructured":"Malladi, S. K. et al. Germinal center-mediated broadening of B cell responses to SARS-CoV-2 booster immunization. Sci. Immunol. 10, eadu4107. https:\/\/doi.org\/10.1126\/sciimmunol.adu4107 (2025).","journal-title":"Sci. Immunol."},{"key":"62635_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-023-06753-7","volume":"625","author":"A Yisimayi","year":"2024","unstructured":"Yisimayi, A. et al. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature 625, 148\u2013156. https:\/\/doi.org\/10.1038\/s41586-023-06753-7 (2024).","journal-title":"Nature"},{"key":"62635_CR24","doi-asserted-by":"publisher","first-page":"888794","DOI":"10.3389\/fimmu.2022.888794","volume":"13","author":"M Graninger","year":"2022","unstructured":"Graninger, M. et al. Heterogeneous SARS-CoV-2-neutralizing activities after infection and vaccination. Front. Immunol. 13, 888794. https:\/\/doi.org\/10.3389\/fimmu.2022.888794 (2022).","journal-title":"Front. Immunol."},{"key":"62635_CR25","doi-asserted-by":"publisher","first-page":"592629","DOI":"10.3389\/fmed.2020.592629","volume":"7","author":"M Koblischke","year":"2020","unstructured":"Koblischke, M. et al. Dynamics of CD4 T cell and antibody responses in COVID-19 patients with different disease severity. Front. Med. (Lausanne). 7, 592629. https:\/\/doi.org\/10.3389\/fmed.2020.592629 (2020).","journal-title":"Front. Med. (Lausanne)"},{"key":"62635_CR26","doi-asserted-by":"publisher","first-page":"946318","DOI":"10.3389\/fimmu.2022.946318","volume":"13","author":"I Medits","year":"2022","unstructured":"Medits, I. et al. Different neutralization profiles after primary SARS-CoV-2 Omicron BA.1 and BA.2 infections. Front. Immunol. 13, 946318. https:\/\/doi.org\/10.3389\/fimmu.2022.946318 (2022).","journal-title":"Front. Immunol."},{"key":"62635_CR27","doi-asserted-by":"publisher","first-page":"e29801","DOI":"10.1002\/jmv.29801","volume":"96","author":"DN Springer","year":"2024","unstructured":"Springer, D. N. et al. Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection. J. Med. Virol. 96, e29801. https:\/\/doi.org\/10.1002\/jmv.29801 (2024).","journal-title":"J. Med. Virol."},{"key":"62635_CR28","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S2666-5247(23)00293-8","volume":"5","author":"DN Springer","year":"2024","unstructured":"Springer, D. N., Medits, I., Weseslindtner, L., Stiasny, K. & Aberle, J. H. SARS-CoV-2 neutralising antibody response to bivalent booster after omicron infection. Lancet Microbe. 5, e8. https:\/\/doi.org\/10.1016\/S2666-5247(23)00293-8 (2024).","journal-title":"Lancet Microbe"},{"key":"62635_CR29","doi-asserted-by":"publisher","first-page":"e29245","DOI":"10.1002\/jmv.29245","volume":"95","author":"L Rossbacher","year":"2023","unstructured":"Rossbacher, L. et al. Effect of previous heterologous flavivirus vaccinations on human antibody responses in tick-borne encephalitis and dengue virus infections. J. Med. Virol. 95, e29245. https:\/\/doi.org\/10.1002\/jmv.29245 (2023).","journal-title":"J. Med. Virol."},{"key":"62635_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-53146-7","author":"D Moll","year":"2026","unstructured":"Moll, D. et al. Validation of an MLV-based SARS-CoV-2 pseudovirus neutralization assay substantiates L455S-mediated antibody escape. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-026-53146-7 (2026).","journal-title":"Sci. Rep."},{"key":"62635_CR31","doi-asserted-by":"publisher","unstructured":"Millet, J. K. & Whittaker, G. R. Murine Leukemia Virus (MLV)-based coronavirus spike-pseudotyped particle production and infection. Bio Protoc. 6, 859. https:\/\/doi.org\/10.21769\/BioProtoc.2035 (2016).","DOI":"10.21769\/BioProtoc.2035"},{"key":"62635_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687. https:\/\/doi.org\/10.1038\/s41586-020-2852-1 (2020).","journal-title":"Nature"},{"key":"62635_CR33","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1038\/s41590-024-01970-2","volume":"25","author":"S Cobey","year":"2024","unstructured":"Cobey, S. Vaccination against rapidly evolving pathogens and the entanglements of memory. Nat. Immunol. 25, 2015\u20132023. https:\/\/doi.org\/10.1038\/s41590-024-01970-2 (2024).","journal-title":"Nat. Immunol."},{"key":"62635_CR34","doi-asserted-by":"publisher","unstructured":"Torresi, J. & Edeling, M. A. Immune imprinting of SARS-CoV-2 responses: changing first immune impressions. mSphere 9, 253. https:\/\/doi.org\/10.1128\/msphere.00758-23 (2024).","DOI":"10.1128\/msphere.00758-23"},{"key":"62635_CR35","doi-asserted-by":"publisher","first-page":"10820","DOI":"10.1038\/s41598-023-38077-x","volume":"13","author":"S Hein","year":"2023","unstructured":"Hein, S. et al. The fourth vaccination with a non-SARS-CoV-2 variant adapted vaccine fails to increase the breadth of the humoral immune response. Sci. Rep. 13, 10820. https:\/\/doi.org\/10.1038\/s41598-023-38077-x (2023).","journal-title":"Sci. Rep."},{"key":"62635_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41541-025-01302-x","volume":"10","author":"AC Pineda-Pena","year":"2025","unstructured":"Pineda-Pena, A. C. et al. Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms. NPJ Vaccines. 10, 260. https:\/\/doi.org\/10.1038\/s41541-025-01302-x (2025).","journal-title":"NPJ Vaccines"},{"key":"62635_CR37","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1056\/NEJMc2213948","volume":"388","author":"Y Collier Ai-ris","year":"2023","unstructured":"Collier Ai-ris, Y. et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N. Engl. J. Med. 388, 565\u2013567. https:\/\/doi.org\/10.1056\/NEJMc2213948 (2023).","journal-title":"N. Engl. J. Med."},{"key":"62635_CR38","doi-asserted-by":"crossref","unstructured":"Tsagkli, P., Geropeppa, M., Papadatou, I. & Spoulou, V. Hybrid immunity against SARS-CoV-2 variants: a narrative review of the literature. Vaccines 12, 859 (2024).","DOI":"10.3390\/vaccines12091051"},{"key":"62635_CR39","doi-asserted-by":"publisher","first-page":"101258","DOI":"10.1016\/j.xcrm.2023.101258","volume":"4","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell. Rep. Med. 4, 101258. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101258 (2023).","journal-title":"Cell. Rep. Med."},{"key":"62635_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1056\/NEJMc2214293","volume":"388","author":"ME Davis-Gardner","year":"2023","unstructured":"Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N Engl. J. Med. 388, 183\u2013185. https:\/\/doi.org\/10.1056\/NEJMc2214293 (2023).","journal-title":"N Engl. J. Med."},{"key":"62635_CR41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41541-023-00708-9","volume":"8","author":"DN Springer","year":"2023","unstructured":"Springer, D. N. et al. Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4\/BA.5) increases neutralization of matched Omicron variants. NPJ Vaccines. 8, 110. https:\/\/doi.org\/10.1038\/s41541-023-00708-9 (2023).","journal-title":"NPJ Vaccines"},{"key":"62635_CR42","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S1473-3099(23)00181-0","volume":"23","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect. Dis. 23, 527\u2013528. https:\/\/doi.org\/10.1016\/S1473-3099(23)00181-0 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"62635_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s43856-024-00457-3","volume":"4","author":"A Reinholm","year":"2024","unstructured":"Reinholm, A. et al. Neutralizing antibodies after the third COVID-19 vaccination in healthcare workers with or without breakthrough infection. Commun. Med. (Lond.). 4, 28. https:\/\/doi.org\/10.1038\/s43856-024-00457-3 (2024).","journal-title":"Commun. Med. (Lond.)"},{"key":"62635_CR44","doi-asserted-by":"publisher","unstructured":"Walmsley, S. et al. Declining levels of neutralizing antibodies to SARS-CoV-2 omicron variants are enhanced by hybrid immunity and original\/omicron bivalent vaccination. Vaccines (Basel) 12, 859. https:\/\/doi.org\/10.3390\/vaccines12060564 (2024).","DOI":"10.3390\/vaccines12060564"},{"key":"62635_CR45","doi-asserted-by":"publisher","unstructured":"Kalkeri, R. et al. Anti-spike IgG4 and Fc effector responses: the impact of SARS-CoV-2 vaccine platform\u2013specific priming and immune imprinting. J. Infect. 91, 968. https:\/\/doi.org\/10.1016\/j.jinf.2025.106543 (2025).","DOI":"10.1016\/j.jinf.2025.106543"},{"key":"62635_CR46","doi-asserted-by":"publisher","first-page":"647934","DOI":"10.3389\/fimmu.2021.647934","volume":"12","author":"L Niu","year":"2021","unstructured":"Niu, L., Wittrock, K. N., Clabaugh, G. C., Srivastava, V. & Cho, M. W. A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain. Front. Immunol. 12, 647934. https:\/\/doi.org\/10.3389\/fimmu.2021.647934 (2021).","journal-title":"Front. Immunol."},{"key":"62635_CR47","doi-asserted-by":"publisher","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042. https:\/\/doi.org\/10.1016\/j.cell.2020.09.037 (2020).","DOI":"10.1016\/j.cell.2020.09.037"},{"key":"62635_CR48","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-020-00318-0","volume":"5","author":"F Yu","year":"2020","unstructured":"Yu, F. et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal. Transduct. Target. Ther. 5, 212. https:\/\/doi.org\/10.1038\/s41392-020-00318-0 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"62635_CR49","doi-asserted-by":"publisher","first-page":"e569","DOI":"10.1016\/S2666-5247(23)00118-0","volume":"4","author":"JM Carreno","year":"2023","unstructured":"Carreno, J. M., Singh, G., Simon, V., Krammer, F. & group, P. V. Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies. Lancet Microbe. 4, e569. https:\/\/doi.org\/10.1016\/S2666-5247(23)00118-0 (2023).","journal-title":"Lancet Microbe"},{"key":"62635_CR50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2213907","volume":"388","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Antibody response to omicron BA.4-BA.5 bivalent booster. N Engl. J. Med. 388, 567\u2013569. https:\/\/doi.org\/10.1056\/NEJMc2213907 (2023).","journal-title":"N Engl. J. Med."},{"key":"62635_CR51","doi-asserted-by":"publisher","unstructured":"Li, W. et al. Potent NTD-targeting neutralizing antibodies against SARS-CoV-2 selected from a synthetic immune system. Vaccines (Basel). 11, 253. https:\/\/doi.org\/10.3390\/vaccines11040771 (2023).","DOI":"10.3390\/vaccines11040771"},{"key":"62635_CR52","doi-asserted-by":"publisher","first-page":"20120","DOI":"10.1038\/s41598-022-24730-4","volume":"12","author":"R Otsubo","year":"2022","unstructured":"Otsubo, R. et al. Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein. Sci. Rep. 12, 20120. https:\/\/doi.org\/10.1038\/s41598-022-24730-4 (2022).","journal-title":"Sci. Rep."},{"key":"62635_CR53","doi-asserted-by":"publisher","first-page":"127997","DOI":"10.1016\/j.vaccine.2025.127997","volume":"69","author":"N Lasrado","year":"2026","unstructured":"Lasrado, N. et al. Immunogenicity of JN.1 and KP.2 COVID-19 mRNA vaccines against emerging SARS-CoV-2 variants. Vaccine 69, 127997. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127997 (2026).","journal-title":"Vaccine"},{"key":"62635_CR54","doi-asserted-by":"publisher","first-page":"114645","DOI":"10.1016\/j.celrep.2024.114645","volume":"43","author":"I Paciello","year":"2024","unstructured":"Paciello, I. et al. Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses. Cell. Rep. 43, 114645. https:\/\/doi.org\/10.1016\/j.celrep.2024.114645 (2024).","journal-title":"Cell. Rep."},{"key":"62635_CR55","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1038\/s41467-024-47451-w","volume":"15","author":"J Pusnik","year":"2024","unstructured":"Pusnik, J. et al. Vaccination impairs de novo immune response to omicron breakthrough infection, a precondition for the original antigenic sin. Nat. Commun. 15, 3102. https:\/\/doi.org\/10.1038\/s41467-024-47451-w (2024).","journal-title":"Nat. Commun."},{"key":"62635_CR56","doi-asserted-by":"publisher","unstructured":"Wang, Z. et al. Ancestral SARS-CoV-2 immune imprinting persists on RBD but not NTD after sequential Omicron infections. iScience 28, 111557. https:\/\/doi.org\/10.1016\/j.isci.2024.111557 (2025).","DOI":"10.1016\/j.isci.2024.111557"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62635-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:50:04Z","timestamp":1792540204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-62635-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["62635"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-62635-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"33145"}}